Your browser doesn't support javascript.
loading
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
Antunes, Liliana; Mazagatos, Clara; Martínez-Baz, Iván; Naesens, Reinout; Borg, Maria-Louise; Petrovic, Goranka; Fatukasi, Terra; Jancoriene, Ligita; Machado, Ausenda; Oroszi, Beatrix; Husa, Petr; Lazar, Mihaela; Dürrwald, Ralf; Howard, Jennifer; Melo, Aryse; Pérez-Gimeno, Gloria; Castilla, Jesús; Bernaert, Eva; Dziugyte, Ausra; Makaric, Zvjezdana Lovric; Fitzgerald, Margaret; Mickiene, Aukse; Gomez, Verónica; Túri, Gergo; Soucková, Lenka; Marin, Alexandru; Tolksdorf, Kristin; Nicolay, Nathalie; Rose, Angela M C.
Afiliação
  • Antunes L; Epidemiology Department, Epiconcept, Paris, France.
  • Mazagatos C; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Martínez-Baz I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Naesens R; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Borg ML; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
  • Petrovic G; Department of Medical Microbiology and Infection Prevention & Control, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium.
  • Fatukasi T; Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.
  • Jancoriene L; Croatian Institute of Public Health, Zagreb, Croatia.
  • Machado A; Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland.
  • Oroszi B; Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
  • Husa P; Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.
  • Lazar M; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
  • Dürrwald R; University Hospital Brno, Masaryk University, Brno, Czechia.
  • Howard J; Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania.
  • Melo A; National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
  • Pérez-Gimeno G; Epidemiology Department, Epiconcept, Paris, France.
  • Castilla J; Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.
  • Bernaert E; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Dziugyte A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Makaric ZL; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Fitzgerald M; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
  • Mickiene A; Department of Medical Microbiology and Infection Prevention & Control, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium.
  • Gomez V; Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.
  • Túri G; Croatian Institute of Public Health, Zagreb, Croatia.
  • Soucková L; Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland.
  • Marin A; Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Tolksdorf K; Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.
  • Nicolay N; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
  • Rose AMC; University Hospital Brno, Masaryk University, Brno, Czechia.
Influenza Other Respir Viruses ; 18(8): e13360, 2024 Aug.
Article em En | MEDLINE | ID: mdl-39145535
ABSTRACT
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Eficácia de Vacinas / Hospitalização Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Assunto da revista: VIROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Eficácia de Vacinas / Hospitalização Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Assunto da revista: VIROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França